TRT: testosterone evidence, costs and access

Here's the short version. Testosterone replacement therapy is a real, FDA-approved hormone treatment with a narrow label and a lot of off-label demand. The rules around it moved twice in 18 months. If hormones are your goal, start with the label, then the price, then the form.

TRT supplies testosterone from outside the body

TRT replaces testosterone the body isn't making enough of. It's a prescription hormone, not a supplement.

That distinction matters for what happens next. Exogenous testosterone can suppress pituitary signaling and sperm production; the effect depends on treatment and individual factors ^[2]. That's why fertility comes up in every TRT conversation, and why some men look at alternatives like enclomiphene first.

Over-the-counter "T boosters" are a separate category. They are marketed as supplements rather than prescribed testosterone; that description does not independently verify their contents or safety.

Who the label covers, and the age question FDA is changing

The FDA label covers adult men with low testosterone from a diagnosed cause, like testicular injury or a pituitary problem. Whether "age-related" low T counts is the part FDA is changing.

The cited DEPO-Testosterone, Xyosted and Jatenzo labels retain a limitation of use: safety and efficacy in men with "age-related hypogonadism" haven't been established ^{[2] [3] [4]}. That line dates to FDA's 2015 safety communication ^[6].

In June 2026, FDA asked makers to remove it, after reviewing TRAVERSE and other data ^[7]. It also asked for revised prostate cancer and enlarged-prostate safety information. Labels change product by product, so the old wording may linger on some for months.

Before starting, these cited labels tell prescribers to confirm the diagnosis with morning blood tests on at least two separate days, both below the normal range ^{[3] [2]}.

What the trials found: selected benefits and cardiovascular noninferiority

In selected men 65 and older, a year of gel improved sexual-function measures and modestly improved mood, but did not meet the primary vitality endpoint. In men at high heart risk, the primary cardiovascular composite met the study’s noninferiority criterion.

TRAVERSE’s primary finding was noninferiority for a defined major cardiovascular composite in selected men, with a 95% hazard-ratio confidence interval of 0.78–1.17. It does not prove no cardiovascular risk in every population, product or duration. It tested gel, not every injection or capsule. The smaller Testosterone Trials could not reliably judge safety ^[10].

What the labels warn about today

Current labels warn about blood pressure increases, blood clots, high red-cell counts, prostate effects and reduced sperm production. Gels add a warning about exposure to children and partners.

• Blood pressure. FDA required new blood-pressure warnings in 2025 after ambulatory monitoring studies ^[6].
• Fertility. "With large doses of exogenous androgens… spermatogenesis may be suppressed," and reduced fertility is seen in some men ^[3]. If you want kids soon, say so at the first visit.
• Prostate. Labels flag worsening of enlarged-prostate symptoms. TRAVERSE screened out high-risk men and saw no significant difference in prostate cancer ^[11].
• Secondary exposure. Children and women should avoid contact with unwashed gel application sites ^[5].
• Who can't take it. Men with breast cancer or known or suspected prostate cancer, and pregnant women ^[2].

The 2025 and 2026 FDA label changes, in order

FDA has moved twice since TRAVERSE. In February 2025 it took heart-risk language out of the boxed warning. In June 2026 it asked makers to drop the age-related limitation ^{[6] [7]}.

Injection, cream or gel, or capsules: three ways to take it

Injection, topical and oral formulations have distinct pharmacology, precautions and monitoring. Gels and creams are applied to the skin. Oral capsules (testosterone undecanoate) are FDA-approved as Jatenzo, Kyzatrex and Tlando ^[4].

The trade-offs are practical: needles vs daily application, transfer risk with gels, and price. Compounded creams aren't FDA-approved products. The full side-by-side is in testosterone injections or cream.

Brand, generic or compounded: what's in the vial matters

FDA-approved testosterone comes as brand or generic products with a label. Compounded testosterone, often the cream, is mixed by a pharmacy for you and isn't an FDA-approved product.

Compounded drugs aren't reviewed by FDA for safety, effectiveness or quality before they're dispensed. That distinction means the label facts in this guide describe the approved products, not every cream on the market.

Ask whether the exact prescription is an FDA-approved brand or generic, or a compounded preparation, and which pharmacy fills it. A familiar ingredient name does not identify its manufacturer or approval status.

What to include in a TRT quote

A current complete quote matters more than an old formulation-wide range. Confirm the exact medication and quantity, initial assessment, baseline and follow-up testing, supplies, shipping and any membership. A compounded cream, approved injection and approved oral capsule are not the same product, even when all contain testosterone.

The billing calculator separates actual fixed-day charges from monthly equivalents. Use the provider checklist to retain the written answers. The Prime Doctor RX review discusses one program’s treatment, laboratory and commitment terms; service availability does not determine whether TRT is appropriate for you.

How to get TRT prescribed: symptoms, two morning labs, a prescriber

Assessment includes symptoms, underlying cause and confirmed laboratory findings; the exact product and intended use determine the applicable label. Remote intake alone does not establish eligibility, a prescription or a pharmacy’s ability to serve your address.

1. Labs first. Two morning testosterone levels on separate days, plus whatever baseline panel the program requires ^[3].
2. A clinician visit. The temporary DEA/HHS rule extends qualifying prescribing without a prior in-person evaluation through December 31, 2026. For testosterone, audio-video and the rule’s prescribing conditions remain relevant; other federal and state requirements still apply ^[8].
3. State rules. Programs don't ship everywhere. Confirm the clinician’s authority, pharmacy authorization and selected treatment availability for your location. A nationwide platform description does not establish every product’s access.
4. Follow-up labs. Expect repeat blood work in the first months. The product label and individual risk determine the schedule; confirm both laboratory and blood-pressure follow-up.

Coverage depends on diagnosis, product, clinician, pharmacy and the insurer’s rules. Confirm clinical-service and medication coverage separately rather than assuming a program’s insurance message covers both.

Five questions to ask a TRT program before you pay

A good program answers these before you hand over a card. If it can't, it isn't ready for you yet.

1. Which labs do you need before the first prescription, and are they in the monthly price?
2. Is the testosterone brand, generic or compounded, and which pharmacy fills it?
3. What does month two cost on the plan I'm picking, and what happens when a prepaid plan ends?
4. How often do you repeat blood counts, PSA and blood pressure checks, and who reviews them?
5. If I want to protect fertility, what do you offer instead, and who decides?

Write the answers down. They're the facts that separate two programs with the same sticker price.

Do GLP-1s or metformin lower testosterone?

The cited Ozempic, Wegovy, Zepbound and metformin labels do not establish low testosterone as a listed adverse reaction ^{[13] [14] [15] [16]}.

That's an absence on a label, not proof of no effect. If you're on one of these drugs and have low-T symptoms, ask your prescriber to check your levels rather than guessing. Retatrutide is different: it lacks an approved commercial label. Routine commercial compounding and properly authorized research or expanded access are separate pathways; see retatrutide’s current access and evidence.

Testosterone for menopause differs from other labeled uses

The cited Xyosted label does not indicate use in women. Some testosterone enanthate labels include a separate palliative metastatic-breast-cancer indication in selected women; that oncology indication does not approve menopause, low desire or general wellness use ^{[3] [1]}.

Some clinicians prescribe testosterone for selected women off-label after clinical assessment. Menopause-program availability is separate from evidence, suitability and product-specific risks. See HRT for the broader menopause-care context.

Alternatives worth comparing before you start

If keeping fertility matters, or your levels are borderline, there are two options people compare with TRT. Neither is a straight swap.

• Enclomiphene nudges your own production instead of replacing it. See enclomiphene or testosterone.
• Sermorelin works on growth hormone, not testosterone. People still weigh it against TRT for energy and body composition: sermorelin or testosterone. Whether it moves testosterone at all is covered in does sermorelin increase testosterone, and the drug itself in sermorelin.
• Comparing two of the bigger online men's programs? Maximus or PeterMD lays them side by side.

Ready to compare programs? The hormones shortlist is the short list. Not sure TRT is your lane? Start the quiz.